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Triple-negative breast cancer (TNBC) accounts for ∼20% of cases
and contributes to basal and claudin-low molecular subclasses of
the disease. TNBCs have poor prognosis, display frequent muta-
tions in tumor suppressor gene p53 (TP53), and lack targeted ther-
apies. The MET receptor tyrosine kinase is elevated in TNBC and
transgenic Met models (Metmt) develop basal-like tumors. To in-
vestigate collaborating events in the genesis of TNBC, we gener-
ated Metmt mice with conditional loss of murine p53 (Trp53) in
mammary epithelia. Somatic Trp53 loss, in combination with Metmt,
significantly increased tumor penetrance over Metmt or Trp53 loss
alone. Unlike Metmt tumors, which are histologically diverse and
enriched in a basal-like molecular signature, the majority of Metmt
tumors with Trp53 loss displayed a spindloid pathology with a dis-
tinct molecular signature that resembles the human claudin-low
subtype of TNBC, including diminished claudins, an epithelial-to-
mesenchymal transition signature, and decreased expression of
the microRNA-200 family. Moreover, although mammary specific
loss of Trp53 promotes tumors with diverse pathologies, those
with spindloid pathology and claudin-low signature display geno-
mic Met amplification. In both models, MET activity is required for
maintenance of the claudin-lowmorphological phenotype, inwhich
MET inhibitors restore cell-cell junctions, rescue claudin 1 expres-
sion, and abrogate growth and dissemination of cells in vivo.
Among human breast cancers, elevated levels ofMET and stabilized
TP53, indicative of mutation, correlate with highly proliferative
TNBCs of poor outcome. This work shows synergy between MET
and TP53 loss for claudin-low breast cancer, identifies a restricted
claudin-low gene signature, and provides a rationale for anti-MET
therapies in TNBC.
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Despite recent improvements in breast cancer mortality, thisdisease remains the second leading cause of cancer-related
deaths for women worldwide (1). Gene expression profiling and
molecular pathology have revealed that breast cancers naturally
divide into luminal A and B, human epidermal growth factor
receptor 2 (HER2)-enriched, basal-like, and the recently iden-
tified claudin-low subtypes (2, 3). Targeted therapies that rely on
tumor cell expression of estrogen and v-erb-b2 erythroblastic
leukemia viral oncogene homolog 2 (ErbB2) receptors can be
effective in the treatment of luminal and HER2-positive breast
cancers (4). However, basal-like and claudin-low breast cancers
are predominately negative for these receptors, referred to as
triple negative (TN), and are associated with poor prognosis. TN
breast cancers account for up to 20% of breast cancer cases (5),
emphasizing the need to identify molecular targets for their
treatment.
Claudin-low tumors were originally distinguished from other
subtypes on the basis of gene expression profiling (3) and have
subsequently been correlated with tumors of metaplastic and
medullary pathology (6). These tumors are characterized by loss of
tight junction markers (notably claudins) and high expression of
markers of epithelial-to-mesenchymal transition (EMT), in addi-
tion to being enriched for markers of mammary stem cells (6).
Signaling throughMET, the receptor tyrosine kinase (RTK) for
hepatocyte growth factor (HGF) influences diverse cellular pro-
cesses during both developmental and cancer progression (7, 8).
MET is expressed in the epithelium of numerous tissues, including
breast, and regulates cell proliferation, migration, and invasion, as
well as EMT (7, 8). Increased expression of MET is associated
with TN breast cancers and correlates with poor outcome (8–11).
In normal breast, activation of MET in ductal epithelium can
occur through paracrine signaling, as a result of the secretion of
HGF by stromal fibroblasts, and increased amounts of HGF are
detected in serum of patients with breast cancer who have high-
grade disease (12, 13).
Transgenic mice expressing a weakly oncogenic variant of Met
under the control of the murine mammary tumor virus (MMTV)
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promoter (MMTV-Metmt), or knock-in of Metmt into its en-
dogenous promoter, develop mammary tumors that are histo-
logically diverse (14, 15). Consistent with elevated MET in TN
breast cancer, 50% of MMTV-Metmt tumors exhibit a molecular
signature of the basal-like subclass of human breast cancer and
are positive for basal cytokeratins (14, 15). However, the long
latency of the MMTV-Metmt model supports the requirement
for cooperating oncogenic events. Loss-of-function mutations in
the tumor suppressor gene TP53 (tumor protein p53) are de-
tected in ∼80% of TN breast cancers (2). Interplay between
TP53 and MET is supported by the observation that in a mouse
model of mammary tumorigenesis involving Trp53 (murine p53)
deletion, 73% of tumors carry amplification of Met (16). More-
over, Met mRNA levels are regulated by the p53-regulated
microRNA (miRNA) miR34a (17). However, synergy between
MET and Trp53 loss during mammary tumor formation has not
been tested.
To study the consequences of Trp53 loss during MET-induced
mammary tumorigenesis, we generated a conditional mouse model
in which mammary gland–specific expression of Met (MMTV-
Metmt) is combined with Cre-recombinase (MMTV-Cre)–medi-
ated deletion of floxed Trp53 alleles in the mammary gland. We
document a significant reduction in tumor latency coupled with
a dramatic increase in tumor penetrance in MMTV-Metmt;
Trp53fl/+;Cre mice compared with MMTV-Metmt and a signifi-
cant increase in penetrance compared with Trp53fl/+;Cre mice.
The majority of mammary tumors that arise in MMTV-Metmt;
Trp53fl/+;Cre mice and Trp53fl/+;Cre mice possess a distinctive
spindloid pathology, and a comparison of gene expression data
with human breast cancer datasets reveals a significant correla-
tion between these mammary tumors and human claudin-low
breast cancer. In both cases, the claudin-low phenotype is cor-
related with amplification of Met and requires continuous MET
signaling. This work highlights the fact that MET and TP53 loss
act synergistically in promoting breast tumors and provides
a model to study the claudin-low subtype.
Results
MMTV-Metmt;Trp53fl/+;Cre Tumors Exhibit a Predominately Spindloid
Pathology. To investigate the consequence of elevated MET in
the absence of functional TP53, we generated a transgenic mouse
model in which mammary gland expression of a weakly oncogenic
MET receptor (MMTV-Metmt) is combined with conditional
deletion of Trp53 in the mammary glands of FVB/N [Friend
Leukaemia virus type B (susceptibility)-NIH] mice (MMTV-
Metmt;Trp53fl/+;MMTV-Cre-recombinase). Compared with
MMTV-Metmt or Trp53fl/+;Cre control mice, we observed a
dramatic increase in tumor penetrance, going from 31% and
24%, respectively, to 70% for MMTV-Metmt;Trp53fl/+;Cre mice
(Table 1 and Fig. 1A). Moreover, although the MMTV-Metmt
model required multiple rounds of pregnancy to stimulate tumor
development, 71% of virgin MMTV-Metmt;Trp53fl/+;Cre mice
developed tumors (Table 1). Unlike the MMTV-Metmt model,
in which a spectrum of tumor pathologies was observed (14),
the majority of mammary tumors that arose in MMTV-Metmt;
Trp53fl/+;Cre mice (80%) and, to a lesser extent, in Trp53fl/+;Cre
mice (63%) displayed a spindloid pathology, with the remaining
tumors being poorly differentiated adenocarcinomas (Fig. 1B).
Cytokeratin (CK) expression can be used to infer the differ-
entiation status of breast tumors (17, 18). Interestingly, although
nonspindloid MMTV-Metmt;Trp53fl/+;Cre and Trp53fl/+;Cre
adenocarcinomas expressed basal (CK14) and luminal (CK8/18)
cytokeratins, as well as CK5 (associated with progenitor cells),
spindloid tumors showed only weak and sporadic expression of
all CKs tested (CK14, 8/18, 5/6) (Fig. S1A). Spindloid tumor cells
stained strongly for the mesenchymal marker vimentin and were
negative for the epithelial marker E-cadherin (Fig. S1), which is
supportive of an EMT (20). Interestingly, coexpression of both
cytokeratins and vimentin was detected by immunofluorescence
in spindloid tumor cells as well as hyperplastic glands (Fig S1B),
thus capturing EMTs. Together, these data support the idea that
expression of activated MET in combination with the loss of
Trp53 in the mouse mammary gland promotes the formation of
tumors with high penetrance and pronounced features that are
typical of EMT.
MMTV-Metmt;Trp53fl/+;Cre and Trp53fl/+;Cre Tumors Undergo Loss of
Heterozygosity for Trp53 and Selectively Amplify the Endogenous
Met Locus. Models of mammary tumorigenesis involving loss of
a single allele of a tumor suppressor gene frequently undergo
loss of heterozygosity during tumor progression, resulting in loss
of the second allele (21). Consistent with this, all MMTV-Metmt;
Trp53fl/+;Cre and Trp53fl/+;Cre mammary tumors tested
showed Cre-mediated deletion of the conditional Trp53 allele as
well as loss of the wild-type (unfloxed) Trp53 allele (Fig. S2). As
loss of TP53 is associated with genomic instability (22), we used
array-based comparative genomic hybridization (aCGH) to inves-
tigate whether consistent chromosomal alterations were asso-
ciated with the MMTV-Metmt;Trp53fl/+;Cre and/or Trp53fl/+;
Cre tumors. In addition to validating loss of the Trp53 locus
(Fig. S3C), array-CGH data also showed copy number changes
consistent with human breast cancer. For example, three of
seven MMTV-Metmt;Trp53fl/+;Cre spindloid tumors (but not
Trp53fl/+;Cre spindloid tumors) showed gain of the locus
encoding myelocytomatosis oncogene (Myc) (MsChr15:61.8Mb)
(Fig. S3), which is amplified in 46.7% of human TN breast cancers
of the claudin-low subclass (23). Although Myc amplification was
not detected in Trp53fl/+;Cre spindloid tumors, both MMTV-
Metmt;Trp53fl/+;Cre tumors and Trp53fl/+;Cre tumors with
a spindloid component contained genomic amplification of the
endogenous Met locus (Chr6 17.4–17.5Mb) (Fig. 1C and Fig. S3).
Although variable, tumors contained a broad region of amplifi-
cation at this locus (Chr6 16.7–18.2Mb), which included not only
Met but also other genes adjacent to Met; including Cav1 (cav-
eolin 1), Cav2 (caveolin 2), Wnt2 (wingless-related MMTV-
integration site 2) and Cftr (cystic fibrosis transmembrane con-
ductance regulator) (Fig. S3). Notably, amplification of Met was
absent in all Trp53fl/+;Cre tumors of adenocarcinoma pathol-
ogy. The association between Met amplification and Trp53-null
mammary tumors of spindloid but not adenocarcinoma-type
pathology is highly significant (P = 0.01786), supporting an as-
sociation between Met amplification and Trp53-deficient tumors
with spindle-cell pathology.
Consistent with Met amplification, MMTV-Metmt;Trp53fl/+;
Cre tumors showed strong immunohistochemical staining for the
endogenous murine MET protein (Fig. 1D). In tumors as well as
tumor lysates, the murine MET protein was highly phosphory-
lated on tyrosines 1234/5 (within the activation loop), consistent
with its amplification and constitutive activation (Fig. 1D and Fig.
S4) (6). This supports a possible “addiction” of the tumors to
MET signaling. Endogenous Met amplification in MMTV-Metmt;
Trp53fl/+;Cre tumors correlated with repression of the MMTV-
Metmt transgene (Fig. 1D and Fig. S4) and is consistent with
suppression of the MMTV promoter after EMT, as shown pre-
viously (24). Notably, Trp53fl/+;Cre spindloid tumors, but not
adenocarcinomas, also expressed elevated levels of endogenous
murine MET at similar levels of activity to that of MMTV-Metmt;
Trp53fl/+;Cre tumors (Fig. S4). Thus, genomic amplification of
Met leads to constitutive activation of the MET RTK in the ab-
sence of its ligand HGF, supporting a potential dependency of
these Trp53-deficient mammary tumors on MET signaling.
MMTV-Metmt;Trp53fl/+;Cre and Trp53fl/+;Cre Spindloid Tumors Are
Characterized by a Strong EMT, Met Signaling Axis, and Significant
Immune Infiltrate.To gain insight into the contribution ofTrp53 loss
to Met-induced mammary tumorigenesis, gene expression profiles
were generated from 14MMTV-Metmt;Trp53fl/+;Cre, 8 Trp53fl/+;
Cre tumors, 8 MMTV-Metmt tumors, and 11 whole mammary
gland (mammary fat pad, MFP) controls. Unsupervised hierar-
chical clustering with those genes that have an interquartile range
greater than or equal to 2 over all samples identified three distinct
clusters (Fig. 2A). The clusters were associated with tumor pa-
thology in which all MMTV-Metmt;Trp53fl/+;Cre and Trp53fl/+;
Cre spindloid tumors clustered together and tumors with an ade-
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nocarcinoma pathology clustered together, regardless of genotype.
Normal mammary gland controls formed a distinct cluster away
from the tumor samples. Genes differentially expressed between
clusters are indicated in Dataset S1, Tables S1–S3.
Compared with MMTV-Metmt tumors or normal MFP
(Dataset S1, Tables S1–S3), a striking feature of MMTV-Metmt;
Trp53fl/+;Cre and Trp53fl/+;Cre spindloid tumors was high
expression of several markers of the previously determined EMT
core signature (Snai1/2, Twist1/2, and Zeb1/2) (Fig. 2 B and C)
(25), weak expression of cytokeratins as observed by immunohis-
tochemical (IHC) analysis (Fig. S1 and Fig. 2B), and decreased
representation of Gene Ontology (GO) and Kyoto Encyclopedia
of Genes and Genomes (KEGG) processes such as cell-cell
junction organization, tight junction, and cell junction mainte-
nance (Fig. 2B and Dataset S1, Tables S4–S7).
Analysis of the genes differentially expressed between MMTV-
Metmt;Trp53fl/+;Cre spindloid and MMTV-Metmt tumors also
identified enrichment for GO and KEGG categories such as actin
filament–based movement and regulation of cell projection orga-
nization (Dataset S1, Table S4 and Fig. 2B), as well as inflammatory
response, positive regulation of macrophage chemotaxis, regula-
tion of lymphocyte-mediated immunity, cytokine-cytokine receptor
interaction, and chemokine signaling pathway (Dataset S1, Table
S5). Consistent with this, high expression of several chemokines
and chemokine receptors associated with monocyte and lympho-
cytic infiltration (Ccr1, Cxcl10, and Cxcl1) (Dataset S1, Table S2)
(26, 27) suggested a strong inflammatory response in MMTV-
Metmt;Trp53fl/+;Cre tumors. Immunostaining for the T- and B-
lymphocyte markers CD3 and CD20 (Fig. S5 A and B) and the
macrophagemarker F4/80 (Fig. S5C) revealed elevated lymphocytic
and macrophage content in MMTV-Metmt;Trp53fl/+;Cre spin-
dloid tumors compared with in MMTV-Metmt tumors.
In addition, the GO analysis included the category HGF re-
ceptor signaling pathway, reflecting a strong MET signaling axis
Table 1. Tumor penetrance and latency values for mammary tumor development in MMTV-
Metmt;Trp53fl/+;Cre, MMTV-Metmt and Trp53fl/+;Cre mice
Parity Genotype
Tumor-bearing mice/
total mice Penetrance, % Latency, d
Nulliparous MMTV-Metmt;Trp53fl/+;Cre 15/21 71.4 278
Trp53fl/+;Cre 4/12 33.3 305
Multiparous MMTV-Metmt;Trp53fl/+;Cre 13/19 68.4 280
Trp53fl/+;Cre 2/13 15 276
MMTV-Metmt 16/52 31 430
Loss of mammary gland expression of Trp53 in the MMTV-Metmt model led to an increase in tumor penetrance
and shortened latency, in addition to abrogating the requirement for parity for tumor development. Compared
with Trp53fl/+;Cre control mice, MMTV-Met;Trp53fl/+;Cre mice developed tumors with a similar latency but at
















































































































































Fig. 1. MMTV-Metmt;Trp53fl/+;Cre mammary
tumors are highly penetrant, have a spindloid
pathology, and selectively amplify the endoge-
nous Met locus. A Kaplan-Meier plot illustrates
that MMTV-Metmt;Trp53fl/+;Cre (n = 35) and
Trp53fl/+;Cre mice (n = 25) have similar tumor
onsets (∼300 d), occurring earlier than tumors in
MMTV-Metmtmice (n=52) (∼400 d) (A). However,
MMTV-Metmt;Trp53;Cre mice are associated with
a significantly higher tumor penetrance (∼70%)
compared with Trp53fl/+;Cre mice (∼24%),
resulting in a steeper curve (A). Tumor pathology
was similar between MMTV-Metmt;Trp53fl/+;Cre
and Trp53fl/+;Cremice, ranging from spindloid to
poorly differentiated adenocarcinomas (B). Cells
with enlarged nuclei (arrow in B, iv) and large
areas of necrosis (outlined in B, iii) were common.
Spindloid tumors often contained ducts with
atypical morphology (Inset, B, ii). All MMTV-
Metmt;Trp53fl/+;Cre tumors contained genomic
amplification of Met and adjacent loci, as de-
termined by array-CGH (C), a phenomenon also
observed in Trp53fl/+Cre tumors of spindloid pa-
thology but not in Trp53fl/+;Cre adenocarcino-
mas (Fig. S2). High expression and activation
(phosphorylation) of endogenousMET inMMTV-
Metmt;Trp53fl/+;Cre andTrp53fl/+;Cre tumorswas
confirmed by immunostaining (D). A Trp53fl/+;
Cre adenocarcinoma without amplification of
Met and little activated MET is shown as a com-
parison (D). (Scale bars, 50 μm.)

















within MMTV-Metmt;Trp53fl/+;Cre tumors (Dataset S1, Table
S4). Consistent with Met amplification and activation, both
MMTV-Metmt;Trp53fl/+;Cre and Trp53fl/+;Cre spindloid
tumors show elevated expression of the Met gene, in addition to
high expression of the MET receptor ligand Hgf, Cd44 (a po-
tential coreceptor for MET) (28), Ets1, and Ybx1 (proposed
transcriptional activators ofMet) (Fig. 2B and Dataset S1, Tables
S1–S3) (29, 30).
MMTV-Metmt;Trp53fl/+;Cre Tumors and Trp53fl/+;Cre Spindloid
Tumors Cluster with the Claudin-Low Subtype of TN Breast Cancers.
To determine whether MMTV-Metmt;Trp53fl/+;Cre and
Trp53fl/+;Cre tumors were representative of a subtype of human
breast cancer, gene expression profiles were compared with
those of Herschkowitz and colleagues (3). Notably, all MMTV-
Metmt;Trp53fl/+;Cre and Trp53fl/+;Cre tumors of spindloid, but
not adenocarcinoma, pathology clustered with the claudin-low
subclass of human breast cancers (Fig. 3A). The human claudin-
low subclass signature reflects high expression of transcriptional
drivers of EMT and low expression of markers of adherens and
tight junctions, such as E-cadherin and claudins 1, 3, 4, and 7 (6).
As validated by quantitative RT-PCR, MMTV-Metmt;Trp53fl/+;
Cre and Trp53fl/+;Cre spindloid tumors showed similar ex-
pression of genes within this signature, expressing high levels of
Snai1/2, Twist1/2, and Zeb1/2 (Fig. 2C) and low levels of claudins
such as Cldn1,3,4 and 7 and E-cadherin (Fig. 2C). Importantly,
application of a claudin-low subclass gene signature derived
from human tumors (6) identified MMTV-Metmt;Trp53fl/+;Cre
and Trp53fl/+Cre spindloid tumors as strongly correlative (P <
0.0001) (Fig. 3B). Conversely, application of the differentially
expressed gene signature fromMMTV-Metmt;Trp53fl/+;Cre and
Trp53fl/+;Cre spindloid tumors to human breast cancer subtypes
induced a cluster of claudin-low subjects, and this human subtype
was found to be highly associated with the signature derived from
the murine spindloid tumors (P < 0.0001) (Fig. S6).
MicroRNA expression profiles are also associated with human
breast cancer pathological features and molecular subtypes (31–
33). Using a signature of ∼50 significantly differentially expressed
miRNAs that distinguish claudin-low tumors from other human
breast cancer subtypes (33), we identified a near-homogeneous
clustering of MMTV-Metmt;Trp53fl/+;Cre and Trp53fl/+;Cre
spindloid tumors that were highly associated with the signature
(P = 0.0004) (Fig. 3C and Dataset S1, Table S8). Notably, consis-
tent with a strong EMT gene expression signature, MMTV-Metmt;
Trp53fl/+;Cre and Trp53fl/+;Cre spindloid tumors showed
a significant decrease in expression of miR-200 family members,
whose targets include the transcription factors Zeb1/2 and are
known inhibitors of EMT and stemness (34–36). Together, these
analyses indicate that MMTV-Metmt;Trp53fl/+;Cre and Trp53fl/+;
Cre spindloid tumors, but not adenocarcinomas, share multiple
features in common with human claudin-low breast cancers.
Identification of a Core Claudin-Low Gene Signature. The human
claudin-low gene signature constitutes 777 genes (6). To establish
whether a restricted, core claudin-low signature could be identi-
fied and whether MMTV-Metmt;Trp53fl/+;Cre and Trp53fl/+;
Cre spindloid tumors share common features with human claudin-
low tumors, we compared genes systematically highly expressed
in MMTV-Metmt;Trp53fl/+;Cre spindloid tumors, Trp53fl/+;Cre
spindloid tumors, human claudin-low tumors, and human basal
B breast cancer cell lines (Fig. 3D). This analysis highlighted
more than 700 genes that are expressed at elevated levels in
either just MMTV-Metmt;Trp53fl/+;Cre or just Trp53fl/+;Cre
tumors, but not the other, a proportional difference that was
significantly higher than expected (P = 0.009). When overall gene
variance was measured, Trp53fl/+;Cre spindloid tumors were
significantly more heterogeneous than MMTV-Metmt;Trp53fl/+;
Cre spindloid tumors (P < 2.2 × 10−16) (Fig. S7). It is possible that
the higher degree of homogeneity observed among MMTV-Met;
Trp53fl/+;Cre tumors may result from expression of the MMTV-
Met transgene at the point of tumor initiation, whereas Trp53-
null-alone tumors arise as a result of more stochastic tumorigenic
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tumors display elevated expression of genes
associated with a mesenchymal, migratory
phenotype and are distinct from MMTV-Metmt
mammary tumors. Unsupervised hierarchical
clustering identifies three distinct groups. In
the first group, 12 MMTV-Metmt;Trp53fl/+;Cre
tumors (blue) form a cluster with six Trp53fl/+;
Cre tumors (yellow) and one MMTV-Metmt
tumor (purple); this cluster represents tumors
of predominantly spindloid pathology and with
genomic amplification of Met. In the next clus-
ter, poorly differentiated adenocarcinomas (two
MMTV-Metmt;Trp53fl/+;Cre and two Trp53fl/+;
Cre tumors) cluster with tumors of the MMTV-
Metmt model. MMTV-Metmt tumors further
segregate into solid and mixed subtypes in
accordance with their pathology (14). Normal
mammary gland controls (green) form the
third cluster. Tumor characterizations below
the heat map are represented in white for
negative, black for positive, and gray for un-
known. “Other_All” refers to tumors of vari-
ous pathology types; for example, tumor
A899 contained regions of spindloid and ad-
enocarcinoma-type pathologies. Genes highly
expressed in MMTV-Metmt;Trp53fl/+;Cre and
Trp53fl/+;Cre spindloid tumors are associated
with cell migration and invasion, signaling
through the MET receptor, and EMT (B). Low
expression of cell-cell junction markers and
moderate expression of epithelial cytoker-
atins is also observed (B). A number of these
genes were validated by qRT-PCR (n = 5 MMTV-Metmt;Trp53fl/+;Cre, 5 Trp53f/+;Cre tumors, 3 MMTV-Metmt mixed tumors, and 3 MMTV-Metmt solid
tumors); expression relative to wild-type mammary gland is shown. Error bars, SEM (C ).
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events subsequent to Trp53 loss. Elevated genes in common be-
tween MMTV-Metmt;Trp53fl/+;Cre spindloid tumors, human
claudin-low tumors, and basal B-cell lines were enriched for
signatures related to EMT, HGF signaling, and immune in-
filtration (Dataset S1, Table S10). In contrast, genes uniquely
elevated in Trp53fl/+;Cre spindloid tumors, human claudin-
low tumors, and basal B-cell lines (but not MMTV-Metmt;
Trp53fl/+;Cre spindloid tumors) had enrichment for sig-
natures related to p53 function such as MDM2 and AURKB
targets, in addition to apoptosis and chemotherapy response
(Dataset S1, Table S10). Hence, although MMTV-Metmt;






































































































































































































































































































































































































Gene Symbol Met;Trp53fl/+;Cre Trp53fl/+;Cre Human CL tumors Basal B cell lines
CAV1 36.5 28.1 2.0 22.2
VIM 22.8 49.9 2.5 17.3
BCAT1 20.1 39.9 1.5 2.5
SEMA3A 19.6 37.0 2.4 1.3
TWIST1 16.0 27.3 1.5 3.2
VEGFC 15.6 12.8 1.6 3.2
EMP3 14.6 16.0 1.6 17.1
TIMP1 12.6 12.4 1.6 3.5
PROCR 10.1 11.4 1.6 4.2
LAMB1 8.1 11.6 1.8 3.3
IL18 8.1 7.1 1.8 1.9
ITGA5 7.4 10.3 1.6 1.9
MSN 7.2 6.7 2.0 9.3
ZEB2 6.7 7.5 2.8 1.2
TUBB6 5.8 4.0 2.1 4.3
RAB32 5.0 6.1 1.6 2.3
FSTL1 5.0 6.4 2.1 5.6
EVI2A 4.9 5.5 2.3 2.9
RAC2 4.9 4.4 3.5 1.8
AP1S2 4.9 5.3 2.6 2.1
AKR1B1 4.9 3.9 2.1 11.6
FSCN1 4.8 5.1 1.2 3.6
COL6A2 4.8 6.2 1.7 3.1
TPST1 4.6 4.2 1.9 1.3
DSE 4.4 5.4 1.7 3.7
STX2 4.4 4.8 1.5 1.5
GNG11 3.9 4.1 1.8 6.5
FLRT2 3.9 7.7 2.3 3.1
CD44 3.9 3.9 1.9 5.0
TGFBI 3.5 3.2 2.5 6.7
YBX1 3.5 3.2 1.5 1.2
HHEX 3.5 4.7 1.9 1.5
SH3BGRL3 3.4 4.0 1.8 2.1
IFI16 3.2 4.3 2.9 7.6
BMP1 3.1 2.9 1.2 1.5





Fig. 3. Gene and miRNA expression profiles of MMTV-Metmt;Trp53fl/+;Cre and Trp53fl/+;Cre spindloid tumors correlate with those of human claudin-low
breast cancer. A cross-species comparison with human breast cancer subtypes reveals that a large proportion of MMTV-Metmt;Trp53fl/+;Cre tumors and
Trp53fl/+;Cre tumors cluster with the claudin-low molecular subclass at the level of gene expression (A). Application of a published claudin-low breast cancer
gene expression signature to the mouse model data confirmed this association (P < 0.0001) (B) and showed that tumors of spindloid pathology were those
that correlated with the signature. Similarly, a significant association in miRNA expression was identified through the application of a human claudin-low
miRNA signature to MMTV-Metmt;Trp53fl/+;Cre and Trp53fl/+;Cre tumor data (P = 4 × 10−4) (C). To further identify genes associated with claudin-low tumor
cell biology and to remove genes expressed by cells in the tumor microenvironment, an intersect of genes highly expressed in human claudin-low breast
cancers, MMTV-Metmt;Trp53fl/+;Cre and Trp53fl/+;Cre spindloid tumors (compared with MMTV-Metmt tumors) and human basal B (claudin-low) breast cancer
cell lines, was generated (D). This comprised 36 genes (E), a selection of which was validated by qRT-PCR (n = 5 MMTV-Metmt;Trp53fl/+;Cre, 5 Trp53f/+;Cre
tumors, 3 MMTV-Metmt mixed tumors, and 3 MMTV-Metmt solid tumors), data were normalized to wild-type mammary gland. Error bars, SEM (F).

















similar to one another than to MMTV-Metmt tumors (Fig. 2A),
these tumors are not identical.
In addition to differences, this analysis generated an intersect
containing 36 genes in common among MMTV-Metmt;Trp53fl/+;
Cre spindloid tumors, Trp53fl/+;Cre spindloid tumors, human
claudin-low tumors, and human basal B breast cancer cell lines
(Fig. 3D). Consistent with the highly mesenchymal phenotype of
our murine as well as human claudin-low tumors, the core 36-
gene intersect includes genes linked to EMT (Twist1, Zeb2, and
Vim) in addition to actin cytoskeleton dynamics (Fscn1) (37),
extracellular matrix interaction, and cell migration (Msn, lamb1,
and Itga5) (38, 39) (Fig. 3 D and E). The 36-gene intersect also
included the proinflammatory cytokine Il-18 and genes associ-
ated with poor-outcome breast cancers [Vegfc (40) and Ybx1
(41)]. To test whether the 36-gene intersect alone could identify
human claudin-low tumors, we applied it to a human breast
cancer dataset containing claudin-low patients (6). Compared
with the published claudin-low predictor of Prat et al. (6), which
includes 426 genes with elevated expression and 351 genes with
decreased, the 36-gene intersect, which represents a small subset,
identified claudin-low patients with an equivalent degree of ac-
curacy as the published predictor (Fig. S8) (P < 0.0001). Thus,
our 36-gene set is functionally equivalent at identifying human
claudin-low tumors while elucidating core aspects of claudin-low
biology, including potential biomarkers.
Claudin-Low EMT Phenotype Is Dependent on MET Kinase. Met was
identified within the intersect of MMTV-Metmt;Trp53fl/+;Cre
tumors, Trp53fl/+;Cre tumors, and basal B-cell lines (Dataset
S1, Table S9) and is also retained as part of the published
claudin-low predictor (6). To establish whether MET is involved
in the maintenance of claudin-low characteristics, primary cells
from MMTV-Metmt;Trp53fl/+;Cre and Trp53fl/+;Cre spindloid
tumors, which amplify the endogenous Met locus and maintain
a strong EMT morphology in culture, were treated with two
small-molecule MET-kinase inhibitors (PHA665752 and Crizo-
tinib) (Fig. S9). On inhibition of MET kinase activity, a striking
change in cell morphology was observed in both MMTV-Metmt;
Trp53fl/+;Cre and Trp53fl/+;Cre tumor cells. Cells lost their
elongated mesenchymal morphology, formed cell-cell junctions
positive for the tight junction marker zona occludens protein 1
(ZO-1), and remodeled their actin cytoskeleton with enhanced
appearance of cortical actin (Fig. 4A). Consistent with the for-
mation of cell-cell junctions and the loss of the EMT morpho-
logical phenotype, elevated levels of Claudin 1 protein (CLDN1)
were observed (Fig. 4B), as well as an elevation in Cldn1
(Claudin 1) and Cdh1 (E-cadherin) mRNA (Fig. 4C). In con-
trast, and surprisingly, mRNA levels of EMT transcriptional
drivers Snail, Twist, and Zeb were not significantly reduced (Fig.
4D). This demonstrates that continued MET signaling has an
important role in regulating cell-cell junction disassembly, even
in the presence of high levels of key EMT regulators, a charac-
teristic of claudin-low tumor pathology.
In addition to restoring tight junctions and reverting the mes-
enchymal cell morphology, MET inhibition resulted in signifi-
cantly impaired proliferation of both MMTV-Metmt;Trp53fl/+;
Cre and Trp53fl/+;Cre spindloid tumor cells, both under normal
(adherent) growth conditions and in soft agar (Fig. 5 A–C). In
addition, Annexin V and propidium iodide labeling revealed
a significant decrease in the viability of cells that had been treated
for 48 h with either PHA665752 or Crizotinib (Fig. 5 D and E).
Together, these data support that both MMTV-Metmt;Trp53fl/+;
Cre and Trp53fl/+;Cre spindloid tumor cells are dependent on
MET activity for their proliferation and survival.
MET Inhibition in Vivo Results in Decreased Metastatic Burden. De-
spite the apparently aggressive phenotype of MMTV-Metmt;
Trp53fl/+;Cre and Trp53fl/+;Cre spindloid tumors, overt lung
metastases were not observed. This may be because of the rapid
proliferation of the primary tumors, which reach biological end-
point within 2 wk postpalpation. Alternatively, metastasis may be
limited by an antitumor immune response, as could be suggested
from the gene expression and immune profiling of these tumors
(Fig. S5). To establish whether these cells are capable of invasive
growth and metastatic spread, as is associated with MET signal-
ing (7), we used a tail vein injection assay to determine whether
MMTV-Metmt;Trp53fl/+;Cre spindloid tumor cells could grow in
the lung microenvironment of immunocompromised mice. In-
troduction of a firefly luciferase gene allowed visualization of
growth in vivo by bioluminescent imaging. MMTV-Metmt;
Trp53fl/+;Cre spindloid tumor cells were highly aggressive, and
by 3 wk postinjection were detected in both the lungs and liver of
injected mice, in addition to other sites such as the lymph nodes
and peritoneal cavity (Fig. 6). Examination of the lung and liver
samples confirmed that MMTV-Metmt;Trp53fl/+;Cre tumor cells
extravasate and proliferate as lesions external to the blood vessels
(Fig. S10), indicating an invasive phenotype. The identification of


















































































































Fig. 4. Treatment of spindloid tumor
cells with pharmacological MET inhib-
itors leads to reversal of the claudin-
low phenotype. MMTV-Metmt;Trp53fl/+;
Cre and Trp53fl/+;Cre spindloid tumor
cells were treated in vitro with small-
molecule inhibitors of MET kinase
(PHA665752 [1 μM] or Crizotinib [1 μM])
for 48–72 h. On treatment, cells under-
went a distinct morphological change
from a mesenchymal to an epithelial-
like state (A), which included the for-
mation of cell-cell junctions, as demon-
strated by the appearance of cortical
actin and localization of ZO-1 at sites of
cell-cell contact (A). (Scale bars, 20 μm.)
This was also accompanied by elevated
levels of Claudin1 protein, as shown by
Western blotting (B). Although we also
observed an increase in mRNA levels of
Claudin1 (Cldn1) and E-cadherin (Cdh1)
on Met inhibition (C), there was no
corresponding decrease in genes that
are well-established as transcriptional
drivers of EMT (Twist1/2, Zeb1/2, and
Snai1/2) (D). Averaged PCR data for four
spindloid tumor cell lines (two MMTV-Metmt;Trp53fl/+;Cre and two Trp53fl/+;Cre lines) are presented. Error bars, SEM.
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cells introduced via the tail vein bypass the normal metastatic
cascade and are delivered directly to the lung, only rarely being
detected in other organs (42–44). Notably, daily treatment of
injected mice with the orally available MET inhibitor Crizotinib
(45 mg·kg−1·d−1) significantly reduced metastatic growth both in
the lungs and livers of the mice (Fig. 6), showing that the meta-
static growth of these EMT mammary tumor cells is highly de-
pendent on MET activity.
Elevated MET and TP53 Protein Correlates with Hormone Receptor-
Negative Status and Poor Prognosis in Human Breast Cancer. Alter-
ations in TP53 are typically associated with the basal subtype of
TN breast cancer (2). Missense mutations are associated with
increased stability of the TP53 protein and can be detected by
IHC analysis, as significantly higher tumor tissue staining is ob-
served compared with tumors with TP53 truncating mutations or
wild-type TP53 (45). Overexpression of MET and expression of
mutant TP53 proteins have both been shown to have prognostic
value individually; however, the significance of their coexistence
in the same tumor has not been examined. The examination of
MET and TP53 protein in a cohort of 618 axillary lymph node–
negative human breast cancer cases (46) revealed that tumor
epithelium was positive for MET immunostaining and/or TP53
staining, with an absence of staining in the stroma (Fig. 7A).
Tumors that stained strongly for MET were more likely to be
TP53 positive than those negative for MET, as 13.9% of all 618
tumors studied were MET+/TP53+ compared with 9.1% that
were MET−/TP53+ (Fig. 7B) (P < 0.0001).
Tumors that scored for both highMET and TP53 were observed
in all histological subtypes, but a significantly greater proportion of
MET/TP53 copositive tumors were estrogen receptor (ER)-nega-
tive, progesterone receptor (PR)-negative, andCK5-positive (61%,
71%, and 44%, respectively) than tumors with other combinations
of MET and TP53 (24%, 38%, and 14%, respectively; P < 0.0001)
(Dataset S1, Table S11). Basal, TN phenotype (TNP)-nonbasal,
Her2, and luminal subtypes were determined as previously de-
scribed (47). MET/P53 copositive tumors were found to correlate
most significantly with the basal (P < 0.0001) and TNP-nonbasal
(P = 0.0211) subtypes (Table 2). More precise identification of
claudin-low patients would require an examination of a claudin-low
gene expression signature within this set and/or the use of a positive
IHC marker for claudin-low, which is currently not known. How-
ever, on the basis of the available information for this cohort, both
of these subtypes could include patients of claudin-low pathology.
The majority of MET/TP53-positive tumors (94%) scored high
for cell proliferation marker KI67 compared with 57% for other
combinations of MET and TP53 (P < 0.0001) (Dataset S1, Table
S11). Consistent with this, combined MET/TP53-positive tumor
status correlates with poor disease-free survival among lymph












































































































































































Met;Trp53fl/+;Cre Untreated DMSO PHA665752 Crizotinib 
Late Apoptotic (%) 8.8 11.7 62*** 12.4 
Early Apoptotic (%) 12.6 8.6 25.6* * 27.4 *** 
Viable (%) 78 79.1 12.1*** 59.4*** 
Trp53fl/+;Cre         
Late Apoptotic (%) 10.5 9.7 79.9*** 8 
Early Apoptotic (%) 13.9 11.9 13.1 22.2 




Fig. 5. Inactivation of MET kinase inhibits the proliferation and survival of Met-amplified spindloid tumor cells. Tumor cells isolated from two MMTV-Metmt;
Trp53fl/+;Cre and two Trp53fl/+;Cre spindloid mammary tumors formed smaller colonies in soft agar during a 10-d assay in the presence of MET kinase
inhibitors (PHA665752 [1 μM] and Crizotinib [1 μM]); representative images for two cell lines are shown (A). (Scale bars, 1,000 μm.) Reduction in colony size
was highly significant in all four cell lines (B). Error bars, SEM. Significantly impaired proliferation resulting from MET inhibition was also demonstrated in a
4-d proliferation assay in which the same cell lines were grown on tissue culture plastic and counted every 24 h (C). Error bars, SEM. To assess any effect on cell
viability, cells treated with MET inhibitors for 48 h were stained with Annexin-V and propidium iodide and analyzed by flow cytometry. Representative plots
for one MMTV-Metmt;Trp53fl/+;Cre cell line are shown (D), and averaged data for two MMTV-Metmt;Trp53fl/+;Cre and two Trp53fl/+ cell lines are tabulated
(E). All four cell lines responded similarly and showed a dramatic increase in the proportion of cells in late-stage apoptosis after treatment with PHA665752
(e.g., 11.7% of MMTV-Metmt;Trp53fl/+;Cre cells were in late apoptosis in the DMSO control vs. 62% in the PHA667572 treatment). The effect of Crizotinib on
cell viability was more moderate (only 12.4% of MMTV-Metmt;Trp53fl/+;Cre cells treated with Crizotinib were in late apoptosis). ***P < 0.01; **P < 0.05 (E).

















with patients with other combinations of MET/TP53 status,
demonstrating that the combination of elevated MET with positive
TP53 IHC is a strong predictor of poor outcome. This associa-
tion persisted in multivariate analysis after adjustment for tra-
ditional histopathological prognostic factors (Dataset S1, Tables
S11 and S12). Finally, MET/TP53 copositivity can also identify
poor-outcome patients within the TN group alone (Fig. 7D).
Together, these results strongly support a role for MET/TP53
signaling in human ER/PR-negative, CK5-positive breast
cancers and in breast cancers with high KI67 staining and
poor outcome.
Discussion
One of the challenges for the effective treatment of breast cancer
is the heterogeneity of the disease (48). TN breast cancers alone
encompass at least 2 (and potentially 6, some of which are more
recently identified) (49) molecular subtypes referred to as basal-
like and claudin-low (3, 6), for which there are a lack of known
therapeutic targets and suitable animal models. Evidence sup-
ports that the MET RTK is elevated in human TN breast cancers
(8). This, together with the observation that murine models
expressing a weakly activated Met in the mammary epithelium
develop tumors with basal-like characteristics, supports a role for
MET in the development of basal-like mammary tumors (14, 15).
However, the involvement of MET in other subtypes within TN
or the ability of MET to synergize with known alterations in TN
breast cancer has not been addressed. To create a more accurate
model for human TN breast cancer, we have exploited the fre-
quent occurrence of TP53 mutations in TN breast cancer and
generated a model combining expression of a weakly oncogenic
MET receptor (MMTV-Metmt) (14) with conditional deletion of
Trp53 in the mammary glands of FVB/N mice (MMTV-Metmt;
Trp53fl/+;MMTV-Cre-recombinase). The resulting MMTV-
Metmt;Trp53fl/+;Cre mouse model shows effective cooperation
of Met with Trp53 loss in mammary tumorigenesis, manifested as
a significant increase in tumor penetrance over both MMTV-
Metmt and Trp53fl/+;Cre control groups.
Notably, the majority of mammary tumors that form in the
MMTV-Metmt;Trp53fl/+;Cre model (80%) share molecular fea-
tures and histological markers of the claudin-low subtype of human
TNbreast cancer (6). Key aspects include enrichment for a claudin-
low gene expression signature (P < 0.0001) (6) and miRNA
signature, including loss of Claudin gene expression (e.g., Cldn1,
Cldn3, Cldn4, and Cldn7), expression of the core EMT gene sig-
nature (Snai1/2, Twist1/2, and Zeb1/2), and lymphocytic infiltration
(6, 23). This phenotype is shared by 5/8 Trp53fl/+;Cre tumors,
which, in addition to loss of Trp53, show amplification of Met and
a similar claudin-low gene expression signature to MMTV-Metmt;
Trp53fl/+;Cre spindloid tumors. In contrast, MMTV-Metmt
tumors clustered with basal and luminal subtypes (14), and only
a single MMTV-Metmt tumor with a spontaneous Trp53mutation,
expressed a claudin-low signature (Fig. 3B). One important dif-
ference within Trp53fl/+;Cre tumors is that Met amplification was
not detected in Trp53fl/+;Cre tumors of adenocarcinoma pathol-
ogy. This indicates that loss ofTrp53 alone, as evident in Trp53fl/+;
Cre adenocarcinomas, is insufficient for spindloid pathology and
a penetrant claudin-low phenotype and supports a synergistic role
for Met, together with Trp53 loss, in promoting tumors with
a spindloid pathology and claudin-low molecular subtype in the
FVB background. This is consistent with the enhanced penetrance
(70%) and high incidence of spindloid (80%), claudin-low-type
tumors in MMTV-Metmt;Trp53fl/+;Cre mice.
Compared with other mouse mammary tumor models,
MMTV-Metmt;Trp53fl/+;Cre and Trp53fl/+;Cre tumors of
spindloid pathology clustered together and in close proximity to
tumors belonging to models such as p53-null transplants, in ad-
dition to 7,12-Dimethylbenz(a)anthracene (DMBA), MMTV-
CreBrca1co/co, and whey acidic protein (WAP)-Myc (Fig. S11).
Interestingly, the WAP-Myc model can also induce tumors of
spindloid pathology (3), and amplification of the Myc locus is
observed in 3 of 7 of the MMTV-Metmt;Trp53fl/+;Cre spindloid
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Fig. 6. MET inhibition impairs the metastatic po-
tential of spindloid mammary tumor cells. An
MMTV-Metmt;Trp53fl/+;Cre spindloid tumor cell line
expressing firefly luciferase was injected i.v. by the
tail vein into 35 nude mice (0.5 × 106 cells/mouse).
Mice were imaged on the day of injection (A) and
twice per week thereafter to monitor the de-
velopment of metastases. A control group of 15 mice
was gavaged daily with water and compared with 20
mice receiving a daily gavage of Crizotinib (45 mg/
kg/d). By day 24, control mice showed extensive
metastatic burden compared with Crizotinib-treated
mice (A). Lungs and livers were harvested from all
animals at day 24 and scored histologically for met-
astatic lesions. Mice treated with Crizotinib showed
a significant reduction in the number of lesions
detected in both the lungs and liver (B). Represen-
tative histology from three control and three Crizo-









































































Negative (1-3) Positive (4 -8)
TP53 IHC Number % Number %
Negative 287 46.4 189 30.6





Fig. 7. Elevated MET expression in human breast cancer is associated with
TP53 mutation and combining MET with TP53 positive IHC identifies patients
with poor prognosis. A human breast cancer tissue microarray comprising 618
node-negative patients was stained forMET and TP53 (A). Analysis showed that
MET-positive tumors were more likely to stain positively for TP53 (indicative of
mutated TP53) than MET-negative tumors (B) and that patients with MET-
positive–TP53-positive tumors had a significantly worse outcome than patients
with either MET or TP53 positivity alone (P = 0.0012) (C). Within TN patients
specifically (n = 93), there was a trend towardMET-TP53 copositivity correlating
with a poorer outcome (P = 0.3774), with a clear separation from patients with
other combinations ofMET and TP53 IHCwithin the first 36mo after diagnosis.
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although 80% of the MMTV-Metmt;Trp53fl/+;Cre tumors de-
scribed here are spindloid or contain a spindle-cell component,
only a fraction of tumors in the aforementioned models display
this phenotype (3). Hence, MMTV-Metmt;Trp53fl/+;Cre tumors
represent a robust model for efficient induction of claudin-low
breast cancer. Similarly, only 10% of tumors arising in a transplant
model of Trp53-null mammary epithelium display a claudin-low
phenotype (50), providing further evidence that loss of Trp53may
be insufficient for this phenotype. Consistent with this, all Trp53fl/+;
Cre tumors of spindloid pathology, correlating with a claudin-low
subtype, contained amplification of the Met locus and variable
adjacent genes. This links MET and P53 synergistically in pro-
moting spindloid pathology and claudin-low like tumors in the
FVB genetic background, especially as Trp53fl/+;Cre tumors of
adenocarcinoma pathology did not amplify Met (Fig. S3A).
Themechanism selecting forMet amplification in the Trp53fl/+;
Cre FVB model is unclear. A similar amplification of Met is
observed in 73% of mammary tumors involving germ-line loss of
Trp53 in combination with a conditional breast cancer 1 (Brca1)
mutation (Brca1Δ11/co;MMTV-Cre;Trp53+/−) (16). However, al-
thoughMet amplification in cell lines established from Brca1Δ11/co;
MMTV-Cre;Trp53+/− tumors was carried on double minutes and
lost from cells in culture (16),Met amplification in cell lines derived
from MMTV-Met;Trp53fl/+;Cre and Trp53fl/+;Cre tumors is
stable and retained during serial passage (Fig. S12). Moreover,
these cell lines are continuously dependent on MET signaling for
their EMT phenotype, as well as for their proliferation and survival
both in culture and in vivo. Thus, Met amplification with conse-
quent constitutive activation of the kinase is required to maintain
the claudin-low mesenchymal phenotype of these cells. The unstable
nature of theMet amplicon in the Brca1Δ11/co;MMTV-Cre;Trp53+/−
model may reflect loss of function of Brca1, which contributes
to chromosomal instability, whereas we observe no decrease in
Brca1 or Brca2 expression in MMTV-Met;Trp53fl/+;Cre tumors
compared with normal mammary gland (Dataset S1, Table S2).
Interestingly, an amplicon containing Met was also recently
detected in murine mammary tumors that arise as a result of po-
tentiated Notch signaling and that also model both basal-like and
claudin-low breast cancers (51). Although the stability of this
amplicon was not addressed in this study, this lends further sup-
port for a specific role for MET signaling in murine models of
claudin-low breast cancer.
Cell explants derived from MMTV-Metmt;Trp53fl/+;Cre and
Trp53fl/+;Cre spindloid claudin-low-like tumors retain a mes-
enchymal phenotype that is highly dependent on continued MET
signaling. When treated with two pharmacological MET inhib-
itors, a reversal of the EMT morphological phenotype was
observed, with elevated levels of Claudin 1 and reformation of
ZO-1 positive cell-cell junctions, which are claudin-dependent
(52). Although the effect of MET signaling on tight junction
disassembly is clear, we observed no changes in the mRNA levels
of the core transcriptional drivers of EMT (Snai1/2, Twist1/2,
and Zeb1/2) on MET inhibition (Fig. 4), demonstrating that con-
tinued MET activation is essential to maintain the EMT mor-
phological phenotype and the loss of claudin gene expression,
a hallmark of human claudin-low tumors (6).
Although MET can promote elevated expression of Zeb1 and
Snail to initiate EMT (14), the core EMT signature is elevated in
Metmt;Trp53fl/+;Cre and Trp53fl/+;Cre spindloid tumors com-
pared with MMTV-Metmt basal subtype tumors. This likely
reflects the role for wild-type Trp53 in promoting an epithelial
phenotype through transcriptional activation of the miR-200
family (underexpressed within the human claudin-low miRNA
signature) that negatively regulates the key regulators of EMT
(34). Consistent with this, after loss of Trp53 in MMTV-Metmt;
Trp53fl/+;Cre and Trp53fl/+;Cre tumors, we observe a decrease
in the miR-200 family and correspondingly high levels of EMT
transcriptional drivers that are not altered after MET inhibition.
Accumulating evidence supports a role for MET and MET-
dependent signals in human claudin-low breast cancer. MET con-
tributes to a published claudin-low predictor (6). A strong MET
signaling network is present in both MMTV-Metmt;Trp53fl/+;Cre
andTrp53l/+;Cre tumors [Hgf,Cd44, Plaur (plasminogen activator,
urokinase receptor), Plau (plasminogen activator, urokinase), Ets1
andYbx1] (28–30, 53, 54), elements of which are also represented in
the 36-gene intersect formed with human claudin-low tumors and
basal B-cell lines (Cd44 and Ybx1) (Fig. 3E). The selection for
amplification of the Met locus in Trp53- null tumors of spindloid
pathology is striking and highlights an emerging concept in cancer
whereby genes that function synergistically to enhance signaling will
frequently be coselected during tumor formation or progression.
We propose that Met synergizes in this context with loss of
function of Trp53 but may also synergize with other regulators
of this phenotype such as Notch (51). The observed amplification
of genes also amplified in human basal and claudin-low breast
cancer such as Caveolin 1 andMyc in the MMTV-Metmt;Trp53fl/+;
Cre model provides a valuable tool to understand the molecular
events and signaling pathways that drive TN breast cancers. This
model also presents an opportunity to study the tumor micro-
environment of claudin-low breast cancer, as demonstrated by
the evidence for robust leukocyte infiltration. Because human
claudin-low breast cancer is especially difficult to treat due to the
lack of biomarkers, determining molecular targets that can be
used in drug therapy is of utmost importance. In addition,
because small-molecule MET inhibitors are presently in clin-
ical trials for multiple cancers, this raises the possibility that
TP53 status may be important for patient selection.
Materials and Methods
Transgenic Mice. MMTV-Metmtmicewere described previously (14). MMTV-Cre
mice were generated in the laboratory of W.J. Muller (55). Mice with floxed-
Trp53 alleles are described elsewhere (21), were obtained from the National
Cancer Institutemouse repository, andwere bredonto a pure FVB background.
Micewere housed in accordancewithMcGill University Animal Ethics Committee
guidelines.
Immunohistochemical and Immunofluorescent Analyses of Mouse Tissue and
Cell Lines. Cells were fixed and histology samples prepared as described in
SI Materials and Methods. Primary and secondary antibodies are detailed in
Dataset S1, Table S13.
Microarray Data. Gene expression profiles were generated using Agilent 4 ×
44K whole-mouse genome gene expression microarrays. Copy number gains
and losses were assessed using Agilent 4 × 44K whole-mouse genome CGH
arrays. miRNA profiling was performed using the Agilent 8 × 15K mouse
miRNA platform. Raw and normalized microarray data have been deposited
in the Gene Expression Omnibus database under accession no. GSE41748. All
analyses are detailed in the SI Materials and Methods.
Isolation and Culture of Mouse Mammary Tumor Cells. Primary cells were
isolated from mouse mammary tumors as described (56). Cells were cultured
Table 2. Association of MET-positive-, TP53-positive breast







TP53 (n = 532)
PNo. % No. %
Basal
Yes 26 30.2 42 7.9 <0.0001
No 60 69.8 490 92.1
TNP-nonbasal
Yes 6 7.0 11 2.0 0.0211
No 80 93.0 521 98.0
Scoring for MET and TP53 IHC on a human breast cancer tissue microarray
was correlated with subtype. Breast cancers that stained positively for both
MET and TP53 were more likely to be classified as basal, than breast cancers
with other combinations of MET and TP53 staining (30.2% vs. 7.9%). Like-
wise, more MET/TP53 copositive breast cancers were classified as TNP-
nonbasal, than breast cancers positive to MET or TP53 alone (7.0% vs. 2.0%).

















in DMEM supplemented with 5% (vol/vol) serum, epidermal growth factor
(5 ng/mL), insulin (5 μg/mL), bovine pituitary extract (35 μg/mL), and hy-
drocortisone (1 μg/mL).
Met Inhibition. MMTV-Metmt;Trp53fl/+;Cre and Trp53fl/+;Cre tumor cell lines
were treated with PHA665752 (Pfizer) or Crizotinib (LC Laboratories) at
a final concentration of 1 μM. Control cells were incubated with an equiv-
alent concentration of DMSO alone for the same amount of time.
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